What is the 13F Pro Quality Score for BBNX?

13F Pro ranks Beta Bionics, Inc. (BBNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BBNX's current score at https://13fpro.ai/research/BBNX (free sign-up required for the full ranking).

Where does 13F Pro source BBNX data?

All Beta Bionics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Beta Bionics, Inc. files with the SEC under CIK 1674632. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BBNX in?

Beta Bionics, Inc. (BBNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BBNX research updated on 13F Pro?

BBNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Beta Bionics, Inc.(BBNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1674632 BBNX stock profile & AI dashboard →

13F Pro Quality Score

22.8/100

Rank #2,631 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

48.1/100

Profitability

7.9/100

Balance Sheet

9.4/100

Earnings Quality

30.0/100

Free Cash Flow

7.6/100

Institutional Flow

88.6/100

Revenue Scale

17.2/100

Dilution Risk

11.5/100

BBNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Beta Bionics, Inc. (BBNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BBNX at 22.8/100 on a 32-signal composite quality model, placing it at rank #2,631 of 2,879 stocks — the bottom half of the AI-ranked universe. BBNX scores in the top quartile across institutional flow (88.6). Areas of concern include free cash flow (7.6) and profitability (7.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Beta Bionics, Inc. reports quarterly revenue of $27.6M, net income of $-21.9M, an operating margin of -87.9%. Top institutional holders of BBNX by reported 13-F value include EVENTIDE ASSET MANAGEMENT,, Soleus Capital Management, L.P., MORGAN STANLEY, based on the most recent SEC filings. BBNX trades on the Nasdaq exchange and files with the SEC under CIK 1674632. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Beta Bionics, Inc. directly from SEC EDGAR. Beta Bionics, Inc.'s 13F Pro composite quality score has ranged between 23 and 43 since 2025, currently 22.8 — a declining long-term trajectory across 10 quarterly and live scoring snapshots.

✦

Fun facts about Beta Bionics, Inc.

Quirks, history, and lore behind BBNX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
A pre-revenue, clinical-stage company — it has spent years burning through capital to bring a single life-changing device to market rather than booking sales.
3
The History
Founded in the 2010s by a team passionate about automating care for people with type 1 diabetes, it grew out of research aimed at building a true artificial pancreas.
4
The Secret
Its flagship system is designed to act like a bionic pancreas — autonomously dosing both insulin and glucagon without the user ever doing the math.
5
The Lore
The company's technology was championed by a Boston University bioengineer whose own child has type 1 diabetes — making this one of the more personal origin stories in medtech.
6
The Giveaway
Its FDA-cleared device, the iLet, is the world's first bionic pancreas — you just tell it your body weight and it figures out the rest.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$27.6M

Net Income

Q1 2026

$-21.9M

Free Cash Flow

Q1 2026

$-25.2M

Operating Margin

Q1 2026

-87.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+53.9% YoY

$100.3MFY 2025

FY22 —FY24 $65.1MFY25 $100.3M

Net Income

-33.7% YoY

$-73.2MFY 2025

FY22 —FY24 $-54.8MFY25 $-73.2M

Operating Income

-58.4% YoY

$-71.7MFY 2025

FY22 —FY24 $-45.3MFY25 $-71.7M

EPS (Diluted)

+79.0% YoY

$-1.81FY 2025

FY22 —FY24 $-8.60FY25 $-1.81

Total Assets

+119.7% YoY

$328.7MFY 2025

FY22 —FY24 $149.6MFY25 $328.7M

Op. Cash Flow

-5.5% YoY

$-50.9MFY 2025

FY22 —FY24 $-48.3MFY25 $-50.9M

Metric	FY 2025	FY 2024	FY 2022
Revenue	$100.3M +53.9%	$65.1M	—
Net Income	$-73.2M -33.7%	$-54.8M	—
Operating Income	$-71.7M -58.4%	$-45.3M	—
EPS (Diluted)	$-1.81 +79.0%	$-8.60	—
Total Assets	$328.7M +119.7%	$149.6M	—
Operating Cash Flow	$-50.9M -5.5%	$-48.3M	—

AI Insight: BBNX Financial Trends

Beta Bionics is burning cash and losses widened sharply in Q1 2026, reversing a four-quarter trend of steady improvement.

• Revenue grew from $18M in Q1 2025 to $32M in Q4 2025, a 78% rise over four quarters, before dipping to $28M in Q1 2026.

• Net loss narrowed consistently from -$29M in Q1 2025 to -$13M in Q4 2025, suggesting improving unit economics through that stretch.

• Operating cash outflow improved from -$20M in Q1 2025 to -$9M in Q4 2025, then reversed sharply to -$24M in Q1 2026.

• Equity has declined every quarter from $314M in Q1 2025 to $271M in Q1 2026, reflecting persistent net losses eroding the balance sheet.

⚠ Q1 2026 operating loss widened to -$24M from -$16M in Q4 2025 — the largest single-quarter deterioration in the dataset.

⚠ Equity runway: at the Q1 2026 burn rate, the $271M equity base faces meaningful erosion without a path to profitability or new capital.

⚠ No debt reported across any quarter — monitor whether the company taps debt markets to extend runway as cash burn re-accelerates.

AI Insight: BBNX Ratio Trends

Beta Bionics remains deeply unprofitable, with Q1 2026 showing a sharp sequential reversal after four quarters of margin improvement.

• Operating margin improved steadily from -105.7% in Q1 2025 to -50.2% in Q4 2025, suggesting meaningful operational progress over that stretch.

• Q1 2026 operating margin deteriorated sharply to -87.9% from -50.2% in Q4 2025, reversing the prior improvement trend.

• ROIC worsened to -35.8% in Q1 2026, the weakest reading in the dataset, down from -22.4% in Q4 2025.

• ROA fell to -28.8% in Q1 2026 versus -16.4% in Q4 2025, indicating asset base is generating deeper losses again.

⚠ Q1 seasonality appears to drive outsized losses; monitor whether Q2 2026 resumes the improvement seen mid-2025.

⚠ D/E data is entirely absent — leverage and balance sheet health cannot be assessed from available data.

⚠ ROIC at -35.8% in Q1 2026 is the worst in the series; sustained negative returns signal ongoing capital destruction risk.

Get alerted when BBNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Beta Bionics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BBNX

EVENTIDE ASSET MANAGEMENT, LLC
$59.6M5,945,488 sh
Soleus Capital Management, L.P.
$43.6M4,354,501 sh
MORGAN STANLEY
$42.4M4,227,634 sh
Sands Capital Ventures, LLC
$37.2M3,708,043 sh
FARALLON CAPITAL MANAGEMENT LLC
$36.2M3,607,920 sh
BlackRock, Inc.
$30.4M3,038,595 sh
Point72 Asset Management, L.P.
$25.3M2,525,040 sh
Vestal Point Capital, LP
$22.2M2,211,518 sh
RTW INVESTMENTS, LP
$20.0M2,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.3M1,727,977 sh

Fund	Value	Shares
EVENTIDE ASSET MANAGEMENT, LLC	$59.6M	5,945,488
Soleus Capital Management, L.P.	$43.6M	4,354,501
MORGAN STANLEY	$42.4M	4,227,634
Sands Capital Ventures, LLC	$37.2M	3,708,043
FARALLON CAPITAL MANAGEMENT LLC	$36.2M	3,607,920
BlackRock, Inc.	$30.4M	3,038,595
Point72 Asset Management, L.P.	$25.3M	2,525,040
Vestal Point Capital, LP	$22.2M	2,211,518
RTW INVESTMENTS, LP	$20.0M	2,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$17.3M	1,727,977

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BBNX on your watchlist

Track score changes the day Beta Bionics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BBNX a good stock to buy?

13F Pro's AI-powered analysis of Beta Bionics, Inc. (BBNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BBNX are available on the BBNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BBNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BBNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Beta Bionics, Inc.'s investment landscape.